Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells to antitumor polyamine-targeted therapies

Tracy Murray-Stewart¹, Matthew Dunworth¹, Yuan Lui¹, Francis M. Giardiello¹,²,³, Patrick M. Woster⁴, Robert A. Casero, Jr¹*

¹ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, ² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, ³ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, ⁴ Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC, United States of America

*rcasero@jhmi.edu

Abstract

Curcumin, a natural polyphenol that contributes to the flavor and yellow pigment of the spice turmeric, is known for its antioxidant, anti-inflammatory, and anticarcinogenic properties. Capable of affecting the initiation, promotion, and progression of carcinogenesis through multiple mechanisms, curcumin has potential utility for both chemoprevention and chemotherapy. Previous studies demonstrated that curcumin can inhibit ornithine decarboxylase (ODC) activity in human leukemia and breast cancer cells, and pretreatment with dietary curcumin blocks carcinogen-induced ODC activity in rodent models of skin, colon, and renal cancer. The current study investigated the regulation of polyamine metabolism in human gastric and colon carcinoma cell lines in response to curcumin. Curcumin treatment significantly induced spermine oxidase (SMOX) mRNA and activity, which results in the generation of hydrogen peroxide, a source of ROS. Simultaneously, curcumin down regulated spermidine/spermine N¹-acetyltransferase (SSAT) activity and the biosynthetic enzymes ODC and S-adenosylmethionine decarboxylase (SAMDC), thereby diminishing intracellular polyamine pools. Combination treatments using curcumin with the ODC inhibitor 2-difluoromethylornithine (DFMO), an agent currently in clinical chemoprevention trials, significantly enhanced inhibition of ODC activity and decreased growth of GI cancer cell lines beyond that observed with either agent alone. Similarly, combining curcumin with the polyamine analogue bis(ethyl)norspermine enhanced growth inhibition that was accompanied by enhanced accumulation of the analogue and decreased intracellular polyamine levels beyond those observed with either agent alone. Importantly, cotreatment with curcumin permitted the lowering of the effective dose of ODC inhibitor or polyamine analogue. These studies provide insight into the polyamine-related mechanisms involved in the cancer cell response to curcumin and its potential as a chemopreventive or chemotherapeutic agent in the GI tract.
Introduction

Curcumin, or diferuloylmethane (1,7-bis(4-hydroxy 3-methoxy phenyl)-1,6-heptadiene-3,5-dione) (Fig 1A) accounts for the characteristic yellow-orange color and flavor of the spice turmeric. Curcuminoids constitute approximately 5% of the crude extract of turmeric root (Curcuma longa), of which curcumin (diferuloylmethane) is the most abundant (60–70%), followed by desmethoxycurcumin (20–27%), and bisdesmethoxycurcumin (10–15%)[1]. As a naturally occurring bioactive polyphenol, curcumin has been used for centuries in traditional medicines for relief from a wide variety of ailments. In addition, it is commonly used in cooking as a spice and food coloring, in skin care products, and as a textile dye. Thus, there exists a long history of safe curcumin use in human populations.

The purported health-promoting properties of curcumin are diverse and include antioxidant, anti-inflammatory, anti-proliferative, anti-angiogenic, and antibacterial activities. This multitude of curcumin effects can likely be attributed to its capacity for modulating certain key signaling pathways with roles in multiple pathologies, including cancer [2]. In addition to chemopreventive potential, curcumin has demonstrated anticancer effects on established tumor cells, which, in contrast to non-tumorigenic cells, often undergo apoptosis and cell death upon exposure to curcumin [3].

The polyamine metabolic pathway plays significant roles in all stages of cancer development. Cancer cells of all types display elevations in polyamine biosynthesis, resulting in intracellular concentrations of polyamines that exceed those of their normal counterparts [4–7]. This consistency across tumor types highlights the importance of polyamines in tumorigenesis and as a potential drug target. Mammals contain three main polyamines, spermine, spermidine, and putrescine (Fig 1B), which, due to their positive charge at physiological pH, readily interact with negatively charged macromolecules, including DNA, RNA, certain proteins, membranes, and ion channels. As a result, polyamines have the ability to affect multiple critical cell processes, including DNA replication, transcription, translation, autophagy, and apoptosis. Thus, their levels must be maintained via tightly controlled regulation.

The dysregulated polyamine metabolism of neoplastic cells involves up regulation of biosynthetic enzymes, down regulation of catabolic enzymes, and increased polyamine uptake from the extracellular environment (Fig 1C) [5, 8–10]. Critical to this loss of homeostasis is an increase in ornithine decarboxylase (ODC) activity, the initial rate-limiting biosynthetic step converting the amino acid ornithine into the diamine putrescine. Rapidly induced by oncogenic stimuli, chemical carcinogens, and tumor promoters, ODC activity is essential for malignant transformation and oncogenesis [9, 11], and the ability of a compound to block this ODC induction is considered an indicator of chemopreventive potential [12]. This is best exemplified by the irreversible ODC inhibitor 2-difluoromethylornithine (DFMO, Fig 1B), or eflo- nithine, which has shown particular promise in clinical trials involving patients predisposed to colorectal tumors [13]. Importantly, curcumin prevents carcinogen- or tumor promoter-induced ODC activity and tumor formation in rodent models of skin, renal, and colon carcinoma (reviewed in [14]). Curcumin also inhibits ODC activity, decreases polyamine levels, and induces apoptosis in multiple breast cancer cell lines [15, 16] and in a promyelocytic leukemia cell line [17].

Therefore, curcumin has demonstrated utility in targeting both the development of cancer and established tumors, and the polyamine metabolic pathway can be targeted to inhibit carcinogenesis in predisposed populations and as a chemotherapeutic target. As the potential for long-term exposure to dietary factors is greatest in the gastrointestinal (GI) tract, the current study comprehensively investigates the effects of curcumin on gastric and colon cancer cell lines with regard to polyamine metabolism including the catabolic pathway. We report for the
first time that curcumin strongly up regulates spermine oxidase (SMOX) while down regulating SSAT and the biosynthetic pathway. The mechanistic importance of these changes is evaluated in the cytotoxic response to curcumin, and novel evidence is provided suggesting the
clinical utility of curcumin in combination with existing modulators of the polyamine pathway in chemopreventive and chemotherapeutic strategies.

**Materials and methods**

**Cell lines and culture conditions**

AGS gastric adenocarcinoma cells (ATCC #CRL-1739, Manassas, VA) were maintained in DMEM/F-12 medium (Mediatech, Manassas, VA) containing 10% fetal calf serum, penicillin and streptomycin at 37°C, 5% CO₂. HCT116 colon carcinoma cells (ATCC #CCL-247) were maintained in McCoy’s 5A medium supplemented with 10% fetal calf serum, penicillin and streptomycin. Pure curcumin provided by the National Cancer Institute was dissolved in sterile DMSO at a concentration of 1 mg/mL and stored at -20°C in single-use aliquots. The polyamine oxidase inhibitor MDL72527 [18] and the polyamine analogue bis(ethyl)norspermine (BENSpm) [19] were synthesized as previously reported. The ornithine decarboxylase inhibitor DFMO was from the Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina. Spermine, spermidine, and aminoguanidine were purchased from Sigma (St. Louis, MO).

**Cell proliferation assays**

AGS or HCT116 cells were seeded in triplicate wells per condition of 96-well plates and allowed to attach overnight. Cells were then treated with 100 μL of fresh medium containing the appropriate concentrations of curcumin, DFMO, BENSpm, MDL72527, and/or 5 μM spermine or spermidine in the presence of 1 mM aminoguanidine to prevent extracellular oxidation by bovine serum oxidase. Following the indicated incubation times, cell viability was determined using the CellTiter 96 AQueous One Solution Cell Proliferation assay (Promega, Madison, WI). Wells without cells were used as blanks for each condition to account for possible variations in absorbance due to the presence of curcumin.

**RNA isolation and quantitative reverse-transcriptase PCR**

Total RNA was isolated from treated cells using TRIzol reagent according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA). One μg of RNA was used for cDNA synthesis using qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD), followed by SYBR green-mediated real-time PCR (Universal SYBR Green Supermix, BioRad, Hercules, CA) using custom primers specific for SMOX, SAT1, AMD1, and ODC (Integrated DNA Technologies, Coralville, IA). Primer pairs were previously optimized using annealing temperature gradients with melt curve analyses and visualization on 2% agarose gels. In each experiment, samples were performed in triplicate, normalized to GAPDH as an internal control, and fold change in expression relative to untreated cDNA was determined using the 2^ΔΔCt algorithm. Thermocycling was performed on a Bio-Rad iQ2 real-time PCR detection system, with data collection facilitated by the iQ5 optical system software.

**Enzyme assays and intracellular polyamine pool determinations**

Lysates from treated cells were used for ODC, SAMDC, and SSAT enzyme activity assays according to previously reported methods [20–22]. Acid-extracted lysate aliquots were labeled with dansyl chloride for fluorometric detection using HPLC as previously described [23]. All enzyme activities and polyamine concentrations were quantified relative to total cellular protein in the lysate, as determined by the method of Bradford [24].
Western blot analyses

Following treatment, cells were lysed in 4% SDS containing protease inhibitors and passed through a homogenizer column (Zymo Research, Irvine, CA). Protein was quantified using the BioRad DC assay with interpolation on a bovine serum albumin standard curve. Reduced samples (30 μg/lane) were separated on 4–12% Bis-Tris BOLT gels (Invitrogen), followed by transfer onto Immun-Blot PVDF (BioRad) and blocking in Odyssey blocking buffer (LI-COR, Lincoln, NE) at room temperature for 1 hour. Membranes were incubated with primary antibodies targeting SMOX, SSAT, ODC, γH2AX (Abcam, Cambridge, MA), and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4˚C. Species-specific, fluorophore-conjugated secondary antibodies were used for visualization and quantitation of bands using an Odyssey infrared detection system and software (LI-COR).

CRISPR-Cas9-mediated generation of SMOX-knockout cell lines

SMOX-knockout cell lines were generated using the CRISPR-Cas9 system. Briefly, single guide RNA (5’- ACCCTCTCAGTCGCGGCCTA-3’) targeting the SMOX gene was cloned into the lentiCRISPR plasmid and viral particles were packaged in HEK293T (ATCC #CRL-3216) cells according to a previously published protocol [25]. Lentiviral particles were then used to transduce AGS cells, and individual clones were selected for resistance to puromycin. Expanded colonies were screened for SMOX knockout by Western blotting.

Statistical analyses

Statistically significant differences were determined as those with p-values less than 0.05, as determined by Student’s t-test using GraphPad software (La Jolla, CA). For combination studies, statistical significance (p < 0.05) was determined by one-way ANOVA with post-hoc analyses.

Results

Curcumin reduces polyamine biosynthesis and intracellular polyamine pools in AGS cells

As curcumin inhibits ODC activity in breast cancer and leukemia cell lines [15, 17], we first determined its effect on ODC mRNA and activity in cancer cell lines of gastrointestinal origin. Not surprisingly, treatment of AGS gastric cancer cells with increasing concentrations of pure curcumin for 48 hours resulted in a dose-dependent decrease in ODC activity, although this decrease was not associated with altered levels of ODC mRNA (Fig 2A). Similarly, curcumin treatment resulted in a non-statistically significant reduction in the enzyme activity of a second rate-limiting enzyme in polyamine biosynthesis, S-adenosylmethionine decarboxylase (SAMDC), without affecting its mRNA transcript level (Fig 2B). HPLC analyses revealed dose-dependent decreases in intracellular concentrations of each of the 3 natural polyamines (Fig 2C). Interestingly, the largest observed reduction was in the higher order polyamine spermine, and this reduction strongly correlated with cell growth inhibition (Fig 2C inset)(R² = 0.977; p < 0.001). Meanwhile, a reduction in spermidine was apparent only at the highest curcumin concentrations. As ODC inhibition typically results in the depletion of putrescine and spermidine pools with variable effects on spermine [26], the pattern observed in response to curcumin is inconsistent with ODC inhibition alone as the mechanism of polyamine depletion, suggesting an induction of polyamine catabolism as an additional regulatory component.
Fig 2. Effects of curcumin on polyamines and their biosynthetic enzymes in AGS cells. AGS gastric carcinoma cells were treated for 48 h with curcumin followed by analyses of mRNA expression and enzyme activity levels of the polyamine biosynthetic enzymes ODC (A) and SAMDC (encoded by the AMD1 gene) (B). (C) Curcumin decreased intracellular polyamine pools and inhibited growth of AGS cells (SPM: spermine; SPD: spermidine; PUT: putrescine). (Inset) Linear regression of spermine concentration versus % of viable cells remaining relative to untreated cells in
Curcumin induces spermine catabolism through spermine oxidase

Due to this reduction in spermine, the effect of curcumin treatment on the polyamine catabolic pathway was investigated. Two options exist for the catabolism of spermine (Fig 1C): (1) acetylation by SSAT to form $N^1$-acetylspermine, which is then either exported from the cell or oxidized back to spermidine via the peroxisomal $N^1$-acetylpolyamine oxidase (PAOX); or (2) direct oxidation back to spermidine by spermine oxidase (SMOX), an enzyme localized both in the nucleus and cytoplasm that produces $H_2O_2$ and 3-aminopropanal as toxic byproducts. Of note, SMOX-generated $H_2O_2$ and its subsequent conversion into a reactive oxygen species (ROS) has been implicated in DNA damage and apoptosis of certain cancer cell types in response to antitumor polyamine analogues [27, 28]. As shown in Fig 3A–3C, treatment of AGS cells with curcumin upregulated both mRNA and protein levels of SMOX. In contrast, SSAT activity (Fig 3E) appeared to be downregulated post-transcriptionally, as curcumin had only a small, insignificant effect on SSAT mRNA abundance (Fig 3D). This is consistent with the loss of SSAT protein stabilization that occurs when polyamine pools are diminished [29]. The observed up regulation of SMOX correlates with the polyamine pool analysis (Fig 2C), suggesting that spermine oxidation contributes to the curcumin-mediated spermine depletion. Of note, curcumin interferes with numerous biochemical assays, including horseradish peroxidase (HRP)-based assays. As spermine oxidase assays measure the production of $H_2O_2$ using luminol- or homovanillic acid-based systems that incorporate HRP, the determination of SMOX enzyme activity in response to curcumin was not possible. Therefore, infrared-based quantitation of Western blots was used to measure SMOX protein induction (Fig 3B and 3C).

Effects of curcumin on polyamine metabolism in HCT116 cells

To further validate our findings in AGS cells, similar experiments were conducted in the HCT116 colon cancer cell line. Unlike AGS cells, HCT116 cells responded to curcumin treatment with decreases in mRNA levels of both ODC and SAMDC, suggesting transcriptional regulation by curcumin (Fig 4A). ODC enzyme activity following curcumin exposure was also decreased, with 4 μg/mL curcumin inhibiting ODC activity by approximately 80% over 24 hours (Fig 4B), substantially exceeding the transcriptional decrease observed and again suggesting an additional level of regulation. Additionally, SMOX mRNA expression and protein levels were induced, and although mRNA expression of SSAT was elevated, protein levels of SSAT decreased, as in AGS cells (Fig 4C and 4D). Analyses of individual polyamine pools following curcumin exposure revealed concurrent, dose-dependent reductions in putrescine, spermidine, and spermine, consistent with greater inhibition of the biosynthetic pathway than that observed in AGS cells as well as the enhancement of spermine catabolism. This reduction in polyamine pools was associated with inhibition of cell growth, as shown in Fig 4E.

SMOX-generated $H_2O_2$ in the apoptotic response to curcumin

Curcumin induces apoptosis through the generation of reactive oxygen species. As a potential ROS, $H_2O_2$ is produced during spermine oxidation, which occurs in the nucleus in close proximity to DNA and chromatin [30], increasing the likelihood of oxidative DNA damage. We therefore investigated the contribution of curcumin-induced SMOX activity in the cytotoxic response of AGS cells using the polyamine oxidase inhibitor MDL72527 as well as CRISPR-
generated genetic SMOX knockout lines. The accumulation of γH2AX, an indicator of DNA damage, was analyzed following curcumin exposure. Although treatment with MDL72527 decreased background levels of γH2AX, no effect was observed on that generated as a result of curcumin exposure (Fig 5A). Likewise, genetic knockout of SMOX in AGS cells failed to reduce the accumulation of DNA damage in response to curcumin (Fig 5B). Furthermore, MTS cell proliferation assays of either wildtype AGS cells cotreated with curcumin and MDL72527 or SMOX knockout clones treated with curcumin indicated no protection from its growth inhibitory effects (Fig 5C), indicating that ROS generated as a result of SMOX induction does not contribute significantly to the oxidative DNA damage or growth inhibition resulting from curcumin treatment. Intracellular polyamine pool analyses revealed reduced spermidine levels in the SMOX KO cell lines (Fig 5D). These results indicate a role for SMOX induction by curcumin as a source of spermidine and suggest that any benefit resulting from a reduction SMOX-generated ROS might be counteracted by increased loss of spermidine.

Fig 3. Curcumin induces spermine catabolism through spermine oxidation in AGS cells. AGS cells were treated for 48 hours and analyzed for SMOX (A) and SSAT (D) mRNA expression via qRT-PCR; (B-C) SMOX and SSAT protein levels by Western blot; and (E) SSAT enzyme activity. Graphs depict the mean values of at least 2 individual experiments, each measured in triplicate. Error bars = SEM; * p < 0.05. A representative western blot is presented in (C).

https://doi.org/10.1371/journal.pone.0202677.g003
Thus, it is likely that alternative mechanisms of ROS generation and growth inhibition are responsible for the DNA damaging and antiproliferative effects of curcumin.

**The role of reduced polyamines in the growth inhibitory response to curcumin**

As mentioned, in both AGS and HCT116 cell lines, the reduction in intracellular polyamine contents closely reflected the inhibition of cell growth. Although reported by others that curcumin is capable of altering intracellular polyamine levels [15, 31], evidence has not been presented implicating or negating a role for polyamine depletion as a mechanism through which
Fig 5. The effects of SMOX induction by curcumin on DNA damage and growth inhibition. (A) AGS cells were treated for 48 h with curcumin in the presence or absence of 250 μM MDL72527, a polyamine oxidase inhibitor. (B) SMOX knockout or control AGS cells were treated for 48 h with increasing concentrations of curcumin. Lysates were analyzed for changes in γH2AX by Western blot. (C) MTS assays were conducted with the same conditions as those in (A) and (B) to determine the effect of SMOX on curcumin-induced growth inhibition. (D) Intracellular spermine (SPM) and spermidine (SPD) levels of SMOX KO cell lines following curcumin exposure for 48 h. Data points indicate the means; error bars represent SEM; n = 3. CT1 and CT2 = CRISPR control AGS cell lines.

https://doi.org/10.1371/journal.pone.0202677.g005
Curcumin exerts growth inhibition. Therefore, rescue experiments were performed to determine if the addition of extracellular polyamines could reduce curcumin-mediated growth inhibitory effects. As shown in Fig 6, incubation of AGS (A) or HCT116 (B) cells for 48 hours in the presence or absence of spermidine or spermine and the bovine serum amine oxidase inhibitor aminoguanidine. MTS assays revealed that exogenous polyamines failed to protect cells from the growth inhibitory effects of curcumin. Data points indicate the means of at least 2 individual experiments, each measured in triplicate, with error bars representing SEM. (C) HPLC analysis of cotreated AGS cells confirmed uptake of spermine and spermidine into the cells, indicating that curcumin did not interfere with polyamine transport. Columns depict the means; error bars indicate SEM; n = 2, each measured in duplicate.

https://doi.org/10.1371/journal.pone.0202677.g006

Fig 6. Polyamine rescue experiments. AGS (A) or HCT116 (B) cells were treated with curcumin for 48 hours in the presence or absence of spermidine or spermine and the bovine serum amine oxidase inhibitor aminoguanidine. MTS assays revealed that exogenous polyamines failed to protect cells from the growth inhibitory effects of curcumin. Data points indicate the means of at least 2 individual experiments, each measured in triplicate, with error bars representing SEM. (C) HPLC analysis of cotreated AGS cells confirmed uptake of spermine and spermidine into the cells, indicating that curcumin did not interfere with polyamine transport. Columns depict the means; error bars indicate SEM; n = 2, each measured in duplicate.
72 h verified that spermine was also being transported and could normalize the curcumin-induced changes in polyamines (S1 Fig). Thus, curcumin-mediated growth inhibition appears to occur through mechanisms independent of polyamine depletion.

**Curcumin cooperates with ODC inhibition to reduce proliferation**

Although the regulation of polyamine metabolism is indeed one of the multiple effects of curcumin in GI cancer cells, it does not appear to play a predominant mechanistic role in the antiproliferative or apoptotic response. However, the knowledge obtained in the studies described thus far provided rationale for exploiting polyamine metabolism as a potential drug target in combination with curcumin. DFMO, a suicide inhibitor of ODC, was examined in cell growth assays in combination with curcumin. As shown in Fig 7A, the addition of curcumin significantly increased the growth inhibitory effects of DFMO over 72 hours in AGS cells. Specifically, treatment with the combination of 1 mM DFMO and 4 μg/mL curcumin (the lowest concentration at which effects on polyamine metabolism were observed) inhibited cell growth by approximately 80%, an increase of ~40% over DFMO alone and approximately 20% beyond curcumin alone. Similarly, while 1 mM DFMO inhibited cell growth of HCT116 cells by approximately 27%, adding curcumin at 6 μg/mL inhibited cell growth by nearly 85% (Fig 7B).

It should be noted that in most tumor cell types, DFMO treatment results in a cytostatic rather than cytotoxic response. Therefore, the possibility that curcumin exacerbates this response may have implications for the clinical use of DFMO, particularly with regard to lowering the effective dose of DFMO and thus minimizing unwanted side effects.

As HCT116 cells maintain high basal levels of ODC activity, we used this cell line to further investigate the effects that combining curcumin with DFMO had on ODC enzyme activity and intracellular polyamine pools. After 24 h, cotreatment with curcumin and DFMO reduced ODC enzyme activity significantly beyond that of either agent alone (Fig 7C), resulting in a 98% inhibition of activity with DFMO at 5 mM. Notably, adding curcumin to each DFMO concentration resulted in ODC inhibition equal to that of an approximately 10-fold greater concentration of DFMO when used alone (e.g., 0.1 mM DFMO with curcumin provided a level of inhibition similar to that of 1 mM DFMO alone). The mean ODC activity level for untreated HCT116 cells in these experiments was approximately 7500 pmol CO₂/mg protein/hour, while curcumin alone decreased ODC activity to ~1600 pmol CO₂/mg protein/hour, as shown in Fig 4B. Polyamine levels in HCT116 cells following the 24-h combination treatment reflected the SMOX-mediated conversion of spermine to spermidine in combination with the DFMO- and curcumin-mediated inhibition of biosynthesis, resulting in an intermediate level of spermidine that was significantly less than that of curcumin treatment alone and greater than DFMO treatment (Fig 7D). The overall effects of the DFMO/curcumin combination treatment are illustrated in Fig 8A.

**Curcumin sensitizes cells to polyamine analogue treatment**

Members of the bis(ethyl) class of polyamine analogues use the polyamine transport system for cellular entry and are capable of reducing polyamine pools through the induction of polyamine catabolism combined with feedback inhibition of biosynthesis [32]. Cellular proliferation assays combining curcumin with the well-studied analogue BENSpm (Fig 1B) demonstrated reduced growth relative to either agent alone in both AGS and HCT116 cells (Fig 9A and S2A Fig, respectively). Analysis of intracellular polyamine pools revealed statistically significant increases in the accumulation of BENSpm in the presence of curcumin over the 72-hour treatment, and these increases coincided with decreases in spermine and spermidine that significantly exceeded those observed with either curcumin or BENSpm alone (Fig 9B and S2B Fig). These results are
consistent with previous studies in which blocking polyamine biosynthesis with specific enzyme inhibitors, such as DFMO, caused increased uptake of polyamines from the extracellular environment [26, 33], but these are the first data indicating this ability for curcumin. As our results

Fig 7. Curcumin cooperates with DFMO to inhibit cell growth. MTS cell proliferation assays revealed enhanced growth inhibition when combining curcumin with the ODC inhibitor DFMO in AGS (A) and HCT116 (B) cells. (C) In HCT116 cells, curcumin combined with DFMO for 24 hours enhanced ODC enzyme inhibition beyond that of single agents. Untreated and curcumin-treated ODC values (~7500 and 1600 pmol/hr/mg protein, respectively) are presented in Fig 4B. \( p < 0.05 \) relative to DFMO alone; \( n = 2 \) individual experiments, each performed in triplicate; error bars = SEM. (D) Changes in individual and total polyamine pools following combination treatment of HCT116 cells for 24 h with 1 mM DFMO and 4 \( \mu \)g/mL curcumin. \( p < 0.05 \) relative to SPD concentration following DFMO or curcumin alone. \( n = 2 \) individual experiments, each measured in duplicate; error bars = SEM. In (A), \( p < 0.05 \) for combinations with 4 \( \mu \)g/mL curcumin and 1 or 5 mM DFMO versus the single agents. In (B), \( p < 0.005 \) for the combination of 6 \( \mu \)g/mL curcumin and 1 mM DFMO, versus single agents. Data points indicate the means of at least 3 independent experiments; error bars = SEM.

https://doi.org/10.1371/journal.pone.0202677.g007
Fig 8. Proposed mechanisms of the combinatorial effects of curcumin with DFMO or BENSpm. Treatment with curcumin alone down regulates the biosynthetic enzymes ODC and SamDC, while up regulating SMOX. The result is decreased putrescine and the conversion of spermine back to spermidine. SSAT activity is lowered, likely due to the decrease in spermine. (A) Adding DFMO further inhibits ODC, reducing the spermidine generated through biosynthesis. Compensatory uptake of polyamines from the extracellular environment would likely be increased by both DFMO and curcumin. (B) Uptake of BENSpm through the polyamine transporter is stimulated by the curcumin-mediated decrease in biosynthesis. BENSpm induces catabolism through SSAT, thereby increasing the depletion of spermine and catabolizing the spermidine accumulated by the induction of SMOX by curcumin. As no accumulation of putrescine is evident, the acetylated polyamines are presumably exported from the cell.

https://doi.org/10.1371/journal.pone.0202677.g008
Fig 9. Curcumin cooperates with BENSpm to inhibit AGS cell growth. (A) MTS cell proliferation assays demonstrated enhanced growth inhibition over 72 h when combining curcumin with the polyamine analogue BENSpm in AGS cells. (B) HPLC analyses revealed increased accumulation of BENSpm in the presence of curcumin, resulting in significant decreases in spermidine and spermine pools. (C) SSAT activity is increased with curcumin/BENSpm cotreatment. (D) Representative Western blot indicating SMOX and SSAT protein levels following combination treatment. (E and F) Infrared imaging-based quantification of SSAT and SMOX Western blots, respectively, relative to actin. In A-F, data points indicate the means of at least 2 independent experiments, measured ≥ 2 times; error bars = SEM. *p < 0.05 relative to single agent treatments.

https://doi.org/10.1371/journal.pone.0202677.g009
(Fig 2A and Fig 4B) and others indicate that curcumin inhibits ODC activity, it is likely that these cells up regulate polyamine transport in order to maintain optimal levels. However, by transporting BENSpm rather than a natural polyamine, polyamine catabolism is induced, further depleting the intracellular concentrations of spermine and spermidine. It is noteworthy that these studies were conducted using 1 μM BENSpm, a dose that, when used as a single agent has no effect on cell growth and elicits minor reductions in the natural polyamine pools. Although BENSpm stimulates both SSAT and SMOX activities, the reduction in both spermine and spermidine suggest a major role for increased SSAT induction as a result of increased analogue uptake in the presence of curcumin. Indeed, SSAT protein and activity were significantly increased when BENSpm was combined with curcumin treatment (Fig 9C–9E). The combination only slightly increased the abundance of SMOX protein beyond that of either agent alone (Fig 9D and 9F). Furthermore, proliferation assays using BENSpm and curcumin in the presence of either pharmacological SMOX inhibition or in SMOX KO cells indicated that induction of SMOX by the combination did not significantly contribute to its inhibitory effects (S3 Fig). The proposed overall mechanism of cooperation between curcumin and BENSpm is illustrated in Fig 8B.

Discussion

Numerous flavonoids commonly found in the diet, including curcumin, can affect polyamine metabolism (reviewed in [14, 34]). Our finding that curcumin inhibits ODC and polyamine biosynthesis in cell lines of gastrointestinal cancer origin is consistent with those reporting ODC inhibition in breast cancer [15, 16] and leukemia cell lines [17]. Although not surprising, this inhibition alone is significant, as ODC activity is often used as a biomarker for tumor progression in animal models of carcinogenesis, and the ability of an agent to inhibit the induction of ODC in these models is associated with its chemopreventive potential [12]. Our novel finding that curcumin simultaneously induces spermine oxidation and reduces intracellular spermine pools, while inhibiting biosynthesis, distinguishes its action from that of the commonly used ODC inhibitor DFMO, which often depletes only putrescine and spermidine. The implications of this could be several, including an increase in oxidative stress, as spermine is a known free radical scavenger [35] and hydrogen peroxide is produced during spermine oxidation [36].

Aside from effects on polyamine metabolism, curcumin shares important anti-inflammatory characteristics with non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and sulindac, including the ability to inhibit cyclooxygenase-2 (COX2), a defining characteristic of traditional NSAIDs [37]. Key to its anti-inflammatory functions, curcumin inhibits activation of the transcription factor nuclear factor kappa B (NF-κB) [38, 39], which targets promoter regions of inflammation- and proliferation-associated genes. NF-κB-regulated gene products include enzymes that produce free radicals, such as inducible nitric oxide synthase (iNOS), lipoxygenase (LOX), and COX2, pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNFα) and interleukins (IL) 1 and 6, and growth-promoting factors such as c-MYC and cyclin D1. As the genes encoding ODC and SAMDC are both driven by c-MYC [40, 41], it is possible that curcumin-mediated inhibition of c-MYC activation might play a role in the transcriptional down regulation of these genes observed in HCT116 cells, which possess high levels of c-MYC. Studies have also shown ODC and SSAT to be regulated by NF-κB [42, 43], although the loss of SSAT activity observed in our cells with curcumin treatment appeared to be due to a post-transcriptional mechanism. Conversely, the high levels of polyamines in tumor cells have been associated with the activation of NF-κB nuclear translocation [44]. Therefore, the reduction of intracellular polyamines by curcumin could hypothetically mediate
its inhibition of NF-κB activation. This ability of curcumin to mediate key factors linking inflammation and cancer is a likely basis for many of its anticarcinogenic activities. Thus, in vivo, in addition to inhibiting polyamine biosynthesis, curcumin may provide added benefits similar to those of NSAIDs through its anti-inflammatory capabilities.

Our current data demonstrating enhanced ODC inhibition and growth arrest when adding curcumin to DFMO indicate the potential of this combination as a chemopreventive regimen. ODC and polyamine levels in neoplastic or tumor tissue are generally increased compared to adjacent normal tissue. In particular, polyps of the colon have elevated polyamine biosynthesis relative to normal colonic mucosa [45–48]. The progression of adenoma to carcinoma is associated with mutation of the adenomatous polyposis coli (APC) gene, which has been detected in 70–80% of sporadic colorectal carcinoma patients and is the major player in several hereditary colon cancer syndromes [49, 50]. Importantly, this mutation results in simultaneous up regulation of ODC as well as COX-1 and COX-2, the therapeutic targets of DFMO and most NSAIDs, respectively, which are also inhibited by curcumin. In a mouse model of familial adenomatous polyposis (FAP) resulting from a mutated Apc allele, dietary curcumin intake decreased adenoma formation by 64% [51]. Dietary curcumin also prevented azoxymethane (AOM)-induced ODC activity in the colonic mucosa of rats, and this was associated with a decreased incidence (>50%) of early preneoplastic lesions in the form of aberrant crypt foci [52]. This same study also reported reductions in AOM-induced LOX and COX metabolites, including prostaglandin E2, in the colonic mucosa of rats receiving dietary curcumin, suggesting that the effects of curcumin overlap with those of NSAIDs in preventing inflammation-associated tumorigenesis. Therefore, curcumin has the potential to limit the activities of key enzymes in individual pathways known to promote carcinogenesis.

The value of our data implicating an enhanced antitumor response when supplementing DFMO treatment with curcumin indicate the potential of this combination as a chemopreventive regimen that would allow reduction of DFMO dose and avoidance of side effects associated with NSAID usage. As chemoprevention involves the long-term administration of a natural or synthetic compound to healthy individuals with the goal of preventing or delaying the onset of disease, the minimization of potential side effects is critical. The overall safety of DFMO has been well established, and it currently retains orphan drug FDA status with approval for the treatment of human African trypanosomiasis and female hirsutism [53]. Although its long-term use was initially associated with a dose-related, reversible ototoxicity, anemia, and mild gastrointestinal side effects, dose de-escalation studies focusing on prevention rather than cancer treatment revealed that DFMO dosage could be reduced to that which minimizes these off-target effects while effectively reducing colorectal mucosa polyamine levels in patients susceptible to colorectal cancer [13, 54]. Notably, in a randomized, placebo-controlled Phase III clinical trial, oral administration of DFMO along with the NSAID sulindac dramatically reduced the occurrence of colorectal adenomas in susceptible patients [55]. In addition to their anti-inflammatory effects, NSAIDs also induce polyamine catabolism through SSAT activity; therefore, combining them with DFMO depleted the levels of intracellular polyamines beyond those required for aberrant proliferation [56], while also providing anti-inflammatory benefits. These combination treatments with NSAIDs have generally allowed a lowering of the effective dose of DFMO required. However, long-term NSAID use can result in injury to the gastrointestinal mucosa as well as renal toxicity, with less frequent but serious side effects manifesting in the cardiovascular and central nervous systems [57]. By cooperating with DFMO to reduce intracellular polyamine concentrations, including spermine, while exerting its anti-inflammatory effects and other modes of action independent of polyamine depletion, curcumin might serve as a safe and perhaps more effective substitute for antitumor curcumin and polyamine-targeted combination therapies
NSAIDs in the chemopreventive setting, particularly for individuals at greater risk for side effects.

Cancer cells, unlike non-tumorigenic cells, generally respond to curcumin exposure with apoptotic cell death [3]. The mechanisms underlying this cancer-cell selectivity include increased curcumin uptake, increased generation of reactive oxygen species (ROS) coincident with reduced levels of intracellular glutathione, and interference with the cancer cell’s reliance on survival signals resulting from constitutive activation of NF-κB [3, 58–60]. In our cancer cell line studies, combining curcumin with DFMO exaggerated the cytostatic response of DFMO into a more cytotoxic one, and we also demonstrated that curcumin has additional modes of action that are independent of polyamine depletion. Furthermore, our data also suggest utility for curcumin/polyamine analogue combinations in the chemotherapeutic arena (Fig 8B). The bis(ethyl) class of polyamine analogues, including bis(ethyl)norspermine (BENSpm, Fig 1B), serve as structural mimetics that compete with the natural polyamines for uptake and binding within the cell. Their accumulation results in a dramatic up regulation of polyamine catabolism while downregulating biosynthesis, depleting the cell of its natural polyamine pools. Importantly, these analogues are unable to fulfill the functional requirements of the natural polyamines, resulting in apoptosis and cell death. As shown in Fig 9 and illustrated in Fig 8B, exposure to curcumin lowered the dose of the bis(ethyl) polyamine analogue BENSpm required to deplete polyamines and arrest growth. This effect was correlated with increased accumulation of BENSpm that was likely due to compensatory uptake in response to the down regulation of biosynthesis by curcumin. Interestingly, this combined reduction of polyamine biosynthesis by curcumin with induction of catabolism and polyamine depletion may have similar effects to those of combining DFMO with NSAIDs, as NSAIDs also induce SSAT to further reduce polyamine pools [56]. The clinical utility of BENSpm has been hampered by dose-limiting toxicities [61]; however, the ability of curcumin to enhance its uptake and accumulation in tumor cells may allow for a reduction in the dosage required for polyamine depletion. Furthermore, a second-generation bis(ethyl) polyamine analogue, PG-11047, has been developed to minimize off-target effects while retaining the functional abilities of BENSpm [62]. PG-11047 has a significantly improved safety profile and is well tolerated in clinical trials (clinicaltrials.gov).

The safe consumption of curcumin is evident in its centuries-long use in traditional medicines as well as through its investigation in nearly 70 completed clinical trials to date (clinicaltrials.gov). In spite of an abundance of promising preclinical studies in many fields of medicine, the clinical success of curcumin in regulated trials has been lacking. Of particular relevance, a double-blind, placebo-controlled clinical trial was recently completed investigating the effect of dietary curcumin administration on the regression of adenomatous polyps in FAP patients [63]. After 1 year, there were no significant differences in polyp number or size between the curcumin and placebo groups. Likewise, polyamine levels in the colonic mucosa of curcumin-treated patients did not significantly differ from those patients receiving placebo. These results are likely due to the known pharmacological limitations of curcumin, including poor solubility and stability and the low overall bioavailability of pure curcumin [2, 64]. Although direct contact with the GI tract potentially lessens the requirement for systemic bioavailability, the results of the abovementioned study still indicate a need for improved pharmacokinetics. Fortunately, several promising strategies are being investigated, including the use of adjuvants that impede curcumin metabolism, curcumin-containing nanoparticles, and structural analogues of curcumin [2, 64].

In conclusion, we have demonstrated that curcumin mediates intracellular polyamine levels in gastrointestinal cancer cell lines through down regulating biosynthesis while up regulating spermine oxidation. Curcumin cooperates with DFMO, an ODC inhibitor approved for
clinical use, to further decrease polyamine biosynthesis and inhibit cell growth, suggesting the potential for curcumin to substitute for NSAIDs in a chemopreventive regimen. Furthermore, through down regulating biosynthesis, curcumin can stimulate uptake of antitumor polyamine analogues, resulting in lower doses required to deplete polyamines and induce tumor cell death. Thus, combining curcumin with modulators of polyamine metabolism holds promise as novel strategies in both chemoprevention and chemotherapeutics.

Supporting information

S1 Fig. Exogenous spermine replenishes intracellular pools. AGS (A) and HCT116 (B) cells were treated with curcumin for 72 hours in the presence or absence of 5 μM spermine and the bovine serum amine oxidase inhibitor aminoguanidine. (B) HPLC analyses confirmed that spermine levels were restored, indicating that curcumin did not interfere with polyamine transport. Columns represent the means of 2 replicates; error bars indicate standard deviations. (TIF)

S2 Fig. Curcumin cooperates with BENSpm to inhibit HCT116 cell growth. (A) MTS cell proliferation assays demonstrated enhanced growth inhibition over 72 h when combining curcumin with the polyamine analogue BENSpm in HCT116 cells. (B) HPLC analyses revealed increased accumulation of BENSpm in the presence of curcumin, resulting in significant decreases in spermidine and spermine pools. Data points indicate the means of at least 2 independent experiments, measured ≥ 2 times; error bars = SEM. *p < 0.05. (TIF)

S3 Fig. The combined growth inhibitory effect of BENSpm and curcumin is independent of SMOX activity. AGS cells were treated with curcumin in the presence or absence of pharmacologic (A) or genetic (B) SMOX inhibition and analyzed for growth inhibition by MTS assays. Data points indicate means; error bars represent SD. (TIF)

Author Contributions

Conceptualization: Tracy Murray-Stewart, Robert A. Casero, Jr.
Data curation: Tracy Murray-Stewart, Matthew Dunworth.
Formal analysis: Tracy Murray-Stewart, Matthew Dunworth.
Funding acquisition: Francis M. Giardiello, Patrick M. Woster, Robert A. Casero, Jr.
Investigation: Tracy Murray-Stewart, Matthew Dunworth, Yuan Lui.
Methodology: Tracy Murray-Stewart, Yuan Lui, Robert A. Casero, Jr.
Project administration: Tracy Murray-Stewart.
Resources: Matthew Dunworth, Francis M. Giardiello, Patrick M. Woster, Robert A. Casero, Jr.
Supervision: Robert A. Casero, Jr.
Validation: Tracy Murray-Stewart.
Visualization: Tracy Murray-Stewart, Patrick M. Woster.
Writing – original draft: Tracy Murray-Stewart.
Writing – review & editing: Tracy Murray-Stewart, Yuan Lui, Francis M. Giardiello, Patrick M. Woster, Robert A. Casero, Jr.

References

1. Nelson KM, Dahl JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017; 60(5):1620–1637. https://doi.org/10.1021/acs.jmedchem.6b00975 PMID: 28074653
2. Kumar G, Mittal S, Sak K, Tuli HS. Molecular mechanisms underlying chemopreventive potential of curcumin: Current challenges and future perspectives. Life Sci. 2016; 148:313–328. https://doi.org/10.1016/j.lfs.2016.02.022 PMID: 26876915
3. Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2. Mol Cancer Ther. 2004; 3(9):1101–1108. PMID: 15367704
4. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988; 48(4):759–772. PMID: 3123052
5. Gerner EW, Meyskens FL Jr. Polyamines and cancer: Old molecules, new understanding. Nat Rev Cancer. 2004; 4(10):781–792. https://doi.org/10.1038/nrc1454 PMID: 15510159
6. Casero RA Jr., Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov. 2007; 6(5):373–390. https://doi.org/10.1038/nrd2243 PMID: 17464296
7. Murray-Stewart TR, Woster PM, Casero RA Jr. Targeting polyamine metabolism for cancer therapy and prevention. Biochem J. 2016; 473(19):2937–2953. https://doi.org/10.1042/BCJ20160383 PMID: 27679855
8. Thomas T, Thomas TJ. Polyamine metabolism and cancer. J Cell Mol Med. 2003; 7(2):113–126. PMID: 12927050
9. Shantz LM, Levin VA. Regulation of ornithine decarboxylase during oncogenic transformation: Mechanisms and therapeutic potential. Amino Acids. 2007; 33(2):213–223. https://doi.org/10.1007/s00726-007-0531-2 PMID: 17443268
10. Casero RA, Pegg AE. Polyamine catabolism and disease. Biochem J. 2009; 421(3):323–338. https://doi.org/10.1042/BJ20090598 PMID: 19589128
11. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature. 1992; 360(6402):355–358. https://doi.org/10.1038/360355a0 PMID: 1280331
12. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: Molecular mechanisms and therapeutic applications. Cell Mol Life Sci. 2001; 58(2):244–258. https://doi.org/10.1007/PL0000852 PMID: 11289306
13. Meyskens FL Jr., Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, et al. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blind trial for colon cancer prevention. Journal of the National Cancer Institute. 1998; 90(16):1212–1218. PMID: 9719082
14. Murray-Stewart T, Casero RA. Regulation of polyamine metabolism by curcumin for cancer prevention and therapy. Med Sci (Basel). 2017; 5(4).
15. Berrak O, Akkoc Y, Arisan ED, Coker-Gurkan A, Obakan-Yerlikaya P, Palavan-Unsal N. The inhibition of PI3K and NFkappaB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in bcl-2 overexpressing Mcf-7 breast cancer cells. Biomed Pharmacother. 2016; 77:150–160. https://doi.org/10.1016/j.biopha.2015.12.007 PMID: 26796279
16. Mehta K, Pantazis P, McQueen T, Aggarwal BB. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs. 1997; 8(5):470–481. PMID: 9215611
17. Liao YF, Hung HC, Hour TC, Hsu PC, Kao MC, Tsay GJ, et al. Curcumin induces apoptosis through an ornithine decarboxylase-dependent pathway in human promyelocytic leukemia HL-60 cells. Life Sci. 2008; 82(7–8):367–375. https://doi.org/10.1016/j.lfs.2007.11.022 PMID: 18187158
18. Bey P, Bolkenius FN, Seiler N, Casara P. N-2,3-butadienyl-1,4-butanediamine derivatives: Potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem. 1985; 28(1):1–2. PMID: 3965702
19. Bergeron RJ, Neims AH, McManis JS, Hawthorne TR, Vinson JR, Bortell R, et al. Synthetic polyamine analogues as antineoplastics. J Med Chem. 1988; 31(6):1183–1190. PMID: 3373487
20. Seely JE, Pegg AE. Ornithine decarboxylase (mouse kidney). Methods Enzymol. 1983; 94:158–161. PMID: 6621384
21. Casero RA Jr., Celano P, Ervin SJ, Porter CW, Bergeron RJ, Libby PR. Differential induction of spermidine/spermine N1-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues. Cancer Res. 1989; 49(14):3829–3833. PMID: 2544259
22. Pegg AE. The role of polyamine depletion and accumulation of decarboxylated S-adenosylmethionine in the inhibition of growth of SV-3T3 cells treated with alpha-difluoromethylornithine. Biochem J. 1984; 224(1):29–38. PMID: 6439194

23. Kabra PM, Lee HK, Lubich WP, Marton LJ. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: Improved separation systems for polyamines in cerebrospinal fluid, urine and tissue. J Chromatogr. 1986; 380(1):19–32. PMID: 3745383

24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248–254. PMID: 942051

25. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale crispr-cas9 knockout screening in human cells. Science. 2014; 343(6166):84–87. https://doi.org/10.1126/science.1247005 PMID: 24336571

26. Mamont PS, Duchesne MC, Grove J, Bey P. Anti-proliferative properties of dl-alpha-difluoromethylornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun. 1978; 81(1):58–66. PMID: 656104

27. Devereux W, Wang Y, Stewart TM, Hacker A, Smith R, Frydman B, et al. Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells. Cancer Chemother Pharmacol. 2003; 52(5):383–390. https://doi.org/10.1007/s00280-003-0662-4 PMID: 12827295

28. Pledger A, Huang Y, Hacker A, Zhang Z, Woster PM, Davidson NE, et al. Spermine oxidase SMO (PAOh1), not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines. J Biol Chem. 2005; 280(48):39843–39851. https://doi.org/10.1074/jbc.M508177200 PMID: 16207710

29. Coleman CS, Pegg AE. Proteasomal degradation of spermidine/spermine N1-acetyltransferase requires the carboxyl-terminal glutamic acid residues. J Biol Chem. 1997; 272(18):12164–12169. PMID: 9115288

30. Murray-Stewart T, Wang Y, Goodwin A, Hacker A, Meeker A, Casero RA Jr. Nuclear localization of human spermine oxidase isoforms—possible implications in drug response and disease etiology. Febts J. 2008; 275(11):2795–2806. https://doi.org/10.1111/j.1742-4658.2008.06419.x PMID: 18422650

31. Thomas TJ, Santhakumar LM, Parikh MS, Thomas T. A possible mechanism for the growth inhibitory action of curcumin on HER-2 over expressing SK-BR-3 breast cancer cells involves the polyamine pathway. Cancer Research. 2004; 64(7 Supplement):168–169.

32. Casero RA Jr., Woster PM. Terminaly alkylated polyamine analogues as chemotherapeutic agents. J Med Chem. 2001; 44(1):1–26. PMID: 11141084

33. Wu Y, Steinbergs N, Murray-Stewart T, Marton LJ, Casero RA. Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes. Biochem J. 2012; 442(3):693–701. https://doi.org/10.1042/BJ20111271 PMID: 22132744

34. Linsalata M, Orlando A, Russo F. Pharmacological and dietary agents for colorectal cancer chemoprevention: Effects on polyamine metabolism (review). Int J Oncol. 2014; 45(5):1802–1812. https://doi.org/10.3892/ij.o.2014.2597 PMID: 25119812

35. Ha HC, Srisomaa NS, Kuppusamy P, Zweier JL, Woster PM, Casero RA Jr. The natural polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci U S A. 1998; 95(19):11140–11145. PMID: 9736703

36. Wang Y, Devereux W, Woster PM, Stewart TM, Hacker A, Casero RA Jr. Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Res. 2001; 61(14):5370–5373. PMID: 11454677

37. Rao CV. Regulation of cox and lox by curcumin. In: Aggarwal BB, Surh Y-J, Shishodia S, editors. The molecular targets and therapeutic uses of curcumin in health and disease. Springer US; 2007. p. 213–226.

38. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995; 270(42):24995–25000. PMID: 7559628

39. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999; 163(6):3474–3483. PMID: 10477620

40. Wagner AJ, Meyers C, Laimins LA, Hay N. c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ. 1993; 4(11):879–883. PMID: 8297793

41. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A. 1993; 90(16):7804–7808. PMID: 8356088

---

PLOS ONE | https://doi.org/10.1371/journal.pone.0202677 August 23, 2018 21 / 23
42. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis. 2004; 25(11):2089–2100. https://doi.org/10.1093/carcin/bgh227 PMID: 15240510

43. Babbar N, Gerner EW, Casero RA Jr. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J. 2006; 394(Pt 1):317–324. https://doi.org/10.1042/BJ20051298 PMID: 16262603

44. Shah N, Thomas T, Shirahata A, Sigal LH, Thomas TJ. Activation of nuclear factor kappaB by polyamines in breast cancer cells. Biochemistry. 1999; 38(45):14763–14774. PMID: 10555958

45. Wallace HM, Caslake R. Polyamines and colon cancer. Eur J Gastroenterol Hepatol. 2001; 13 (9):1033–1039. PMID: 11564951

46. Luk GD, Baylin SB. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med. 1984; 311(2):80–83. https://doi.org/10.1056/NEJM198407123110202 PMID: 6738598

47. Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA Jr. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res. 1997; 57(2):199–201. PMID: 9000553

48. Rial NS, Meyskens FL Jr., Gerner EW. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. Essays Biochem. 2009; 46:111–124. https://doi.org/10.1042/bse0460008 PMID: 20095973

49. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759–767. PMID: 2188735

50. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6:479–507. https://doi.org/10.1146/annurev-pathol-011110-130235 PMID: 21090969

51. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the mini+ mouse, a model of familial adenomatous polyposis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002; 11(6):535–540.

52. Rao CV, Simi B, Reddy BS. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis. 1993; 14(11):2219–2225. PMID: 8242846

53. LoGiudice N, Le L, Abuian I, Leizorek Y, Roberts SC. Alpha-difluoromethylornithine, an irreversible inhibitor of polyamine biosynthesis, as a therapeutic strategy against hyperpluriferative and infectious diseases. Med Sci (Basel). 2018; 6(1).

54. Meyskens FL Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999; 5(5):945–951. PMID: 10353725

55. Meyskens FL Jr., McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008; 1(1):32–38.

56. Gerner EW, Meyskens FL Jr. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 2009; 15(3):758–761. https://doi.org/10.1158/1078-0432.CCR-08-2235 PMID: 19188144

57. Tsioulias GJ, Go MF, Rigas B. Nsaisid and colorectal cancer control: Promise and challenges. Curr Pharm Accel. 2015; 1(5):285–301. https://doi.org/10.1007/s40495-015-0042-x PMID: 26688785

58. Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity. J Biol Chem. 2005; 280(26):25284–25290. https://doi.org/10.1074/jbc.M414645200 PMID: 15879598

59. Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta. 2008; 1789(4):673–679. https://doi.org/10.1016/j.bbagen.2007.11.016 PMID: 18178166

60. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2002; 2(4):301–310. https://doi.org/10.1038/nrc780 PMID: 12001991

61. Hahm HA, Ettinger DS, Bowling K, Hoker B, Chen TL, Zabelina Y, et al. Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer. Clin Cancer Res. 2002; 8(3):684–689. PMID: 11895896

62. Reddy VK, Valasinas A, Sarkar A, Basu HS, Marton LJ, Frydman B. Conformationally restricted analogues of 1N,12N-bisethylnorspermine: Synthesis and growth inhibitory effects on human tumor cell lines. J Med Chem. 1998; 41(24):4723–4732. https://doi.org/10.1021/jm980172v PMID: 9822543

63. Cruz-Correa M, Hylind LM, Marrero JH, Zahurak ML, Murray-Stewart T, Casero RA Jr., et al. Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology. 2018.
64. Adiwidjaja J, McLachlan AJ, Boddy AV. Curcumin as a clinically-promising anti-cancer agent: Pharmacokinetics and drug interactions. Expert Opin Drug Metab Toxicol. 2017; 13(9):953–972. https://doi.org/10.1080/17425255.2017.1360279 PMID: 28776444